

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of)
Kjell OLMARKER et al.	Group Art Unit: .1647
Application No.: 09/760,810) Examiner: J. Seharaseyon
Filed: January 17, 2001	Confirmation No.: 4391

USE OF CERTAIN For:

> **METALLOPROTEINASE INHIBITORS** FOR TREATING NERVE DISORDERS MEDIATED BY NUCLEUS PULPOSUS

FEB 2:8 2003 TECH CENTER 1600/2900

INFORMATION DISCLOSURE STATEMENT TRANSMITTAL LETTER

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

Enclosed is an Information Disclosure Statement and accompanying form PTO-1449 for the above-identified patent application.

[X]	No additional fee for submission of an IDS is required.	
[]	The fee of \$180.00 (1806) as set forth in 37 C.F.R. § 1.17(p) is also enclosed.	
[X]	A statement under 37 C.F.R. § 1.97(e) is also enclosed.	
[]	A statement under 37 C.F.R. § 1.97(e), and the fee of \$180.00 (1806) as set forth in 37 C.F.R. § 1.17(p) are also enclosed.	
[]	Charge \$ to Deposit Account No. 02-4800 for the fee due.	
[]	A check in the amount of \$ is enclosed for the fee due.	

The Commissioner is hereby authorized to charge any appropriate fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 02-4800. This paper is submitted in duplicate.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

P.O. Box 1404 Alexandria, Virginia 22313-1404 (703) 836-6620

Date: February 26, 2003